Cargando…
Impact of a Health Management Program on Healthcare Outcomes among Patients on Augmentation Therapy for Alpha 1-Antitrypsin Deficiency: An Insurance Claims Analysis
INTRODUCTION: Alpha 1-antitrypsin deficiency (AATD) is a genetic disorder which reduces serum alpha 1-antitrypsin (AAT or alpha1-proteinase inhibitor, A1PI) and increases the risk of chronic obstructive pulmonary disease (COPD). Management strategies include intravenous A1PI augmentation, and, in so...
Autores principales: | Campos, Michael A., Runken, Michael C., Davis, Angela M., Johnson, Michael P., Stone, Glenda A., Buikema, Ami R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910458/ https://www.ncbi.nlm.nih.gov/pubmed/29616482 http://dx.doi.org/10.1007/s12325-018-0690-4 |
Ejemplares similares
-
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009) -
Detection of alpha-1 antitrypsin deficiency: the past, present and future
por: Brantly, Mark, et al.
Publicado: (2020) -
The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency
por: Campos, Michael A., et al.
Publicado: (2018) -
Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach
por: Stockley, Robert A, et al.
Publicado: (2013) -
New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2020)